...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urology practice. >Review of New Implantable Tibial Nerve Stimulators in Comparison to Established Third Line Treatment Modalities for Nonneurogenic Overactive Bladder
【24h】

Review of New Implantable Tibial Nerve Stimulators in Comparison to Established Third Line Treatment Modalities for Nonneurogenic Overactive Bladder

机译：综述新的植入胫骨神经刺激器与非致原膀胱内膀胱的第三线治疗方式相比

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: New technologies are currently evolving in the treatment of overactive bladder syndrome, giving physicians and patients additional options when conservative care fails to resolve symptoms. The purpose of this review is to compare the prospective clinical data of the new small implantable devices stimulating the tibial nerve to recent prospective clinical studies of sacral nerve stimulation, percutaneous tibial nerve stimulation and botulinum toxin injection, which are currently the most established third line treatment modalities in overactive bladder syndrome.Methods: A literature search on PubMed?/MEDLINE? was performed for new technologies in neuromodulation to improve overactive bladder syndrome. Additionally, a search was performed for all currently established third line treatment options for comparison of treatment results. The reported prospective clinical data were statistically compared using Fisher's exact test.Results: Two new small implantable devices that stimulate the tibial nerve have been reported over the recent years, Blue Wind RENOVA? and eCoin?. These new implantable devices that stimulate the tibial nerve show very comparable 3-month and 6-month clinical success rates regarding reduction of urinary incontinence episodes when compared to well-established treatment options such as sacral nerve stimulation, percutaneous tibial nerve stimulation and botulinum toxin injections.Conclusions: The 2 new small implantable devices stimulating the tibial nerve, BlueWind RENOVA and eCoin, show promising clinical results. Both devices are currently undergoing U.S. Food and Drug Administration approval and 1-year followup data should soon be available. Still more clinical data with larger patient cohorts and multicenter studies are necessary to verify the therapeutic efficacy of these new small implantable devices. If confirmed these new small implantable neuromodulation devices may become well-established in the treatment of patients with overactive bladder syndrome.
机译：导言：目前，治疗膀胱过度活动综合征的新技术正在不断发展，当保守治疗无法解决症状时，医生和患者可以有更多的选择。本综述的目的是将刺激胫神经的新型小型植入式装置的前瞻性临床数据与骶神经刺激、经皮胫神经刺激和肉毒毒素注射的近期前瞻性临床研究进行比较，这是目前公认的膀胱过度活动综合征的第三线治疗方式。方法：对PubMed/MEDLINE？为改善膀胱过度活动综合征而进行的神经调节新技术研究。此外，还对目前确定的所有第三线治疗方案进行了搜索，以比较治疗结果。使用Fisher精确检验对报告的前瞻性临床数据进行统计比较。结果：近年来，有报道称有两种新的小型植入式装置刺激胫神经，即Blue Wind RENOVA？还有eCoin？。与骶神经刺激、经皮胫神经刺激和肉毒毒素注射等公认的治疗方案相比，这些刺激胫神经的新型植入式装置在减少尿失禁发作方面显示出非常相似的3个月和6个月临床成功率。结论：BlueWind RENOVA和eCoin这两种刺激胫神经的新型小型植入式装置显示了良好的临床效果。这两种设备目前都在接受美国食品和药物管理局的批准，一年的随访数据应该很快就能得到。为了验证这些新型小型植入式设备的治疗效果，还需要更大的患者队列和多中心研究的更多临床数据。如果得到证实，这些新的小型植入式神经调节装置可能在治疗膀胱过度活动综合征患者方面得到广泛应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号